Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma

Journal of Neuro-Oncology

Volumn 123, Issue 2, 2015, Pages 277-282

  Nagpal, Seema ^a   Recht, Cathy Kahn ^a   Bertrand, Sophie ^a   Thomas, Reena Parada ^a   Ajlan, Abdulrazag ^a   Pena, Justine ^a   Gershon, Megan ^a   Coffey, Gwen ^a   Kunz, Pamela L ^b   Li, Gordon ^a   Recht, Lawrence D ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bevacizumab; Etirinotecan pegol; Glioblastoma; Glioma

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICONVULSIVE AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ATROPINE; BEVACIZUMAB; CARMUSTINE; CORTICOSTEROID DERIVATIVE; ETIRINOTECAN PEGOL; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; MACROGOL DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN EDEMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPOSI SARCOMA; LIFE EXPECTANCY; LOOSE FECES; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PREDICTION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIOSURGERY; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; BRAIN NEOPLASMS; CANCER GRADING; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; POLYETHYLENE GLYCOLS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84930375264     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1795-0     Document Type: Article

References (24)

1. Ajaz M, Jefferies S, Brazil L, Watts C, Chalmers A (2014) Current and investigational drug strategies for glioblastoma. Clin Oncol 26(7):419–430. doi:10.1016/j.clon.2014.03.012
2. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73(15):1200–1206. doi:10.1212/WNL.0b013e3181bc0184
3. Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G, Wick W, Bendszus M, Radbruch A (2014) Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 82(19):1684–1692. doi:10.1212/WNL.0000000000000402
4. Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY (2009) Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11(5):550–555. doi:10.1215/15228517-2009-006
5. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745. doi:10.1200/JCO.2008.16.3055
6. Chamberlain MC, Grimm S, Phuphanich S, Recht L, Zhu JZ, Kim L, Rosenfeld S, Fadul CE, Brain Tumor Investigational Consortium (2014) A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC). J Neurooncol 118(2):335–343. doi:10.1007/s11060-014-1437-y
7. Jaeckle K, Schiff D, Anderson SK, Galanis E, Stella PJ, FlynnPJ, Sarkaria JN, Giannini C, Erickson BJ, Buckner JC (2013) NCCTG (Alliance) N0572: a phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi). J Clin Oncol 31 (supp; abstract 2014)
8. Norden AD Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Muzikansky A, Dietrich J, Smith KS, GaffeySC, McCluskey CS, Ligon KL, Reardon DA, Wen PY (2013) Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas. J Clin Oncol 31 (suppl; abstr TPS2104)
9. Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U (2013) Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. J Neurooncol 111(2):205–212. doi:10.1007/s11060-012-1009-y
10. Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA (2014) Phase II trial of 7 days on/7 days off temozolomide for recurrent high-grade glioma. Neuro Oncol 16(9):1255–1262. doi:10.1093/neuonc/nou044
11. Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, Fine HA (2013) Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol 111(1):41–48. doi:10.1007/s11060-012-0988-z
12. Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA (2011) A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 13(4):437–446. doi:10.1093/neuonc/noq198
13. Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I (2013) Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 15(2):242–250. doi:10.1093/neuonc/nos295
14. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17(5):1516–1525
15. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740. doi:10.1200/JCO.2008.19.8721
16. Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL (2003) Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 97(9 Suppl):2381–2386. doi:10.1002/cncr.11306
17. Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikcevich DA, Wiesenfeld M, Jaeckle KA, Galanis E, North Central Cancer Treatment Group (2009) Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol 92(2):165–175. doi:10.1007/s11060-008-9749-4
18. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF (1977) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252(11):3582–3586
19. Abuchowski A, van Es T, Palczuk NC, Davis FF (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252(11):3578–3581
20. Knop K, Hoogenboom R, Fischer D, Schubert US (2010) Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem 49(36):6288–6308. doi:10.1002/anie.200902672
21. Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD (2013) A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res 19(1):268–278. doi:10.1158/1078-0432.CCR-12-1201
22. Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O’Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, DE Young, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA, Group N-S (2013) Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. The Lancet Oncology 14(12):1216–1225. doi:10.1016/S1470-2045(13)70429-7
23. Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, Reed N, Dark G, Fracasso PM, Ibrahim EN, Armenio VA, Duska L, Poole C, Gennigens C, Dirix LY, Leung AC, Zhao C, Soufi-Mahjoubi R, Rustin G (2013) Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. J Clin Oncol 31(32):4060–4066. doi:10.1200/JCO.2012.45.1278
24. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65(1–2):271–284